Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
INCAGN1876 (GITR) |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
INCAGN1876 (GITR)
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
Indatuximab Ravtansine |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Indatuximab Ravtansine
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Indoximod |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Indoximod
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Inebilizumab (Onc Adjacent) |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Inebilizumab (Onc Adjacent)
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Istiratumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Istiratumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Ivonescimab |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
Ivonescimab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
Lemzoparlimab |
CD47 (Macrophage Checkpoint) Inhibitor | Hematologic | ||
|
Molecule
Lemzoparlimab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
CD47 (Macrophage Checkpoint) Inhibitor |
||||
Letaplimab |
CD47 (Macrophage Checkpoint) Inhibitor | Hematologic | ||
|
Molecule
Letaplimab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
CD47 (Macrophage Checkpoint) Inhibitor |
||||
Linrodostat |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Linrodostat
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Lumretuzumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Lumretuzumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Luveltamab Tazevibulin |
Anti-FOLR1 ADC, Hemiasterlin Payload | Solid Tumour | ||
|
Molecule
Luveltamab Tazevibulin
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-FOLR1 ADC, Hemiasterlin Payload |
||||
Magrolimab |
CD47 (Macrophage Checkpoint) Inhibitor | Hematologic | ||
|
Molecule
Magrolimab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
CD47 (Macrophage Checkpoint) Inhibitor |
||||
INCAGN1876 (GITR)Immunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
Indatuximab RavtansineTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
IndoximodTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
Inebilizumab (Onc Adjacent)Targeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
IstiratumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
IvonescimabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
LemzoparlimabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
CD47 (Macrophage Checkpoint) Inhibitor |
|
LetaplimabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
CD47 (Macrophage Checkpoint) Inhibitor |
|
LinrodostatTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
LumretuzumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Luveltamab TazevibulinTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-FOLR1 ADC, Hemiasterlin Payload |
|
MagrolimabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
CD47 (Macrophage Checkpoint) Inhibitor |
|